Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | Director | February 13, 2023 | February 15, 2023 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date February 13, 2023 · Filed February 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 3,604 |
Reported balance
After 2023-02-13 transaction · row 1
1 source rowRow 1 · 2023-02-13 · Grant · Acquired 3,604 · Balance 3,604 F1: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.
MIMEDX GROUP, INC.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 108,510 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 50,913 · Balance 108,510 F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next meeting of shareholders.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 3,255 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share underlying such Company RSU Award immediately prior to the Effective Time. F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on August 12, 2022. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-12-22 · Disposition to issuer · Disposed 11,335 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share underlying such Company RSU Award immediately prior to the Effective Time.
F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on August 12, 2022.
Mirror Merger Sub 2, LLC
Report date March 01, 2021 · Filed March 03, 2021
Section 16 reporting ended · disclosed 2021-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Eaton Vance Corp. Non-voting Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 1
1 source rowRow 1 · 2021-03-01 · Disposition to issuer · Disposed 23,981 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 7, 2020 (the Merger Agreement), by and among Issuer, Morgan Stanley, Mirror Merger Sub 1, Inc. and Mirror Merger Sub 2, LLC, in exchange for $1,750,613.00. |
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-01 · Disposition to issuer · Disposed 9,372 · Balance 0 F2: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F3: This Deferred Stock Unit award was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $684,156.00. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.23 · Expires 2022-11-01 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-01 · Disposition to issuer · Disposed 5,680 · Balance 0 F4: This option award, which was granted on November 1, 2012, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $254,310.13. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.76 · Expires 2025-11-02 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-01 · Disposition to issuer · Disposed 7,451 · Balance 0 F5: This option award, which was granted on November 2, 2015, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $270,024.24. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.71 · Expires 2024-11-03 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-01 · Disposition to issuer · Disposed 5,737 · Balance 0 F6: This option award, which was granted on November 3, 2014, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $208,195.73. |
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-01 · Disposition to issuer · Disposed 3,252 · Balance 0 F7: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock. F8: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 7, 2020 (the Merger Agreement), by and among Issuer, Morgan Stanley, Mirror Merger Sub 1, Inc. and Mirror Merger Sub 2, LLC, in exchange for $1,750,613.00.
F2: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock.
F3: This Deferred Stock Unit award was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $684,156.00.
F4: This option award, which was granted on November 1, 2012, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $254,310.13.
F5: This option award, which was granted on November 2, 2015, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $270,024.24.
F6: This option award, which was granted on November 3, 2014, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $208,195.73.
F7: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock.
F8: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2017 Filed Aug 15, 2017 11:17 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 12 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-013988 · doc4.xml · derivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,048 Underlying: Eaton Vance Corp. Non-voting Common Stock · 12 shares Expires 2018-11-01 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Phantom Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Phantom Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 16:10 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 1,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-011393 · edgar.xml · nonDerivative · entry 1 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,032 F3 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the later of: (a) August 9, 2018; or (b) the date of the Issuer's next annual meeting of stockholders. F3 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the later of: (a) August 9, 2018; or (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 06, 2017 Filed Jun 7, 2017 14:18 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionOption (right to buy) · Derivative | 4,883 | $0.00 Strike: $27.50 | $0.00 |
DisclosureSEC source: 0001225208-17-010986 · doc4.xml · derivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Eaton Vance Corp. Non-voting Common Stock · 4,883 shares Expires 2019-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 7, 2017 14:18 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | SaleEaton Vance Corp. Non-voting Common Stock | 2,563 | $48.46 | $124,194.78 |
DisclosureSEC source: 0001225208-17-010986 · doc4.xml · nonDerivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,910 F1 · shares: Shares were sold to cover the cost of exercising a NQ stock option. Read SEC document |
| June 06, 2017 Filed Jun 7, 2017 14:18 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionEaton Vance Corp. Non-voting Common Stock | 4,883 | $27.50 | $134,258.09 |
DisclosureSEC source: 0001225208-17-010986 · doc4.xml · nonDerivative · entry 1 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2017 Filed May 15, 2017 14:24 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 11 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009699 · doc4.xml · derivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,567 Underlying: Eaton Vance Corp. Non-voting Common Stock · 11 shares Expires 2017-11-02 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Phantom Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Phantom Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| May 15, 2017 Filed May 15, 2017 14:24 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 14 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009699 · doc4.xml · derivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Underlying: Eaton Vance Corp. Non-voting Common Stock · 14 shares Expires 2018-11-01 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Phantom Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Phantom Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:03 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001179110-17-006992 · edgar.xml · derivative · entry 5 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires 2018-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F3 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · derivative.exercise_date: This option becomes exerciseable in full on the date set forth in Table II, Column 6. Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:03 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock, $0.01 par value | 1,111 | $132.50 | $147,211.06 |
DisclosureSEC source: 0001179110-17-006992 · edgar.xml · nonDerivative · entry 4 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,749 F3 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $132.0500 and $133.4175. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:03 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock, $0.01 par value | 5,758 | $131.42 | $756,708.87 |
DisclosureSEC source: 0001179110-17-006992 · edgar.xml · nonDerivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,860 F3 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $131.0500 and $132.0350. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:03 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock, $0.01 par value | 6,631 | $130.63 | $866,236.04 |
DisclosureSEC source: 0001179110-17-006992 · edgar.xml · nonDerivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,618 F3 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $130.0200 and $131.0100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:03 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock, $0.01 par value | 13,500 | $18.63 | $251,505.00 |
DisclosureSEC source: 0001179110-17-006992 · edgar.xml · nonDerivative · entry 1 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| February 15, 2017 Filed Feb 15, 2017 14:34 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 10 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003356 · doc4.xml · derivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,556 Underlying: Eaton Vance Corp. Non-voting Common Stock · 10 shares Expires 2017-11-02 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Phantom Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Phantom Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| February 15, 2017 Filed Feb 15, 2017 14:34 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 13 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003356 · doc4.xml · derivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,022 Underlying: Eaton Vance Corp. Non-voting Common Stock · 13 shares Expires 2018-11-01 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Phantom Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Phantom Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| December 13, 2016 Filed Dec 14, 2016 16:38 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionStock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0001179110-16-032951 · edgar.xml · derivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2017-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan. F4 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · derivative.exercise_date: This option becomes exerciseable in full on the date set forth in Table II, Column 6. Read SEC document |
| December 13, 2016 Filed Dec 14, 2016 16:38 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock, $0.01 par value | 8,000 | $120.00 | $960,000.00 |
DisclosureSEC source: 0001179110-16-032951 · edgar.xml · nonDerivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,749 F4 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| December 13, 2016 Filed Dec 14, 2016 16:38 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock, $0.01 par value | 8,000 | $12.69 | $101,520.00 |
DisclosureSEC source: 0001179110-16-032951 · edgar.xml · nonDerivative · entry 1 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 10:14 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 12 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-041906 · doc4.xml · derivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,546 Underlying: Eaton Vance Corp. Non-voting Common Stock · 12 shares Expires 2017-11-02 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Phantom Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Phantom Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 14:10 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionPhantom Stock · Derivative | 1,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-041255 · doc4.xml · derivative · entry 4 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Eaton Vance Corp. Non-voting Common Stock · 1,448 shares Expires 2016-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 14:10 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 11 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-041255 · doc4.xml · derivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,448 Underlying: Eaton Vance Corp. Non-voting Common Stock · 11 shares Expires 2016-11-03 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. F2 · shares: As dividends are paid with respect to Company Non-Voting Common Stock, a number of units of Phantom Stock with a current value equal to the amount of the dividend will be allocated to the account of each non-employee Director with respect to each unit of Phantom Stock Awarded at the time such dividends are paid to the stock holders of the Company. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 14:10 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Disposition to issuerEaton Vance Corp. Non-voting Common Stock | 1,448 | $34.99 | $50,665.52 |
DisclosureSEC source: 0001225208-16-041255 · doc4.xml · nonDerivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,590 Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 14:10 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionEaton Vance Corp. Non-voting Common Stock | 1,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-041255 · doc4.xml · nonDerivative · entry 1 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 18:42 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantPhantom Stock · Derivative | 2,009 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-041042 · doc4.xml · derivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,009 Underlying: Eaton Vance Corp. Non-voting Common Stock · 2,009 shares Expires 2018-11-01 F1 · security: Each share of Phantom Stock is the economic equivalent of one share of non-voting common stock. The shares of Phantom Stock become payable in cash at the earlier of the second anniversary of the grant date or the date of the non-employee director's termination. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 18:42 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | GrantOption (right to buy) · Derivative | 11,777 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0001225208-16-041042 · doc4.xml · derivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,777 Underlying: Eaton Vance Corp. Non-voting Common Stock · 11,777 shares Expires 2026-11-01 Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 15:01 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionOption (right to buy) · Derivative | 8,197 | $0.00 Strike: $29.39 | $0.00 |
DisclosureSEC source: 0001225208-16-039566 · doc4.xml · derivative · entry 3 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Eaton Vance Corp. Non-voting Common Stock · 8,197 shares Expires 2016-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 15:01 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | SaleEaton Vance Corp. Non-voting Common Stock | 6,197 | $38.75 | $240,123.22 |
DisclosureSEC source: 0001225208-16-039566 · doc4.xml · nonDerivative · entry 2 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,590 F1 · shares: Shares were sold to cover the cost of exercising a NQ stock option. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 15:01 UTC | Mirror Merger Sub 2, LLC EV · Entity 141944 | Exercise / conversionEaton Vance Corp. Non-voting Common Stock | 8,197 | $29.39 | $240,897.53 |
DisclosureSEC source: 0001225208-16-039566 · doc4.xml · nonDerivative · entry 1 PUHY DOROTHY E · CIK 0001200493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.